Page 2 - Vstm News Today

By Ben Glickman Verastem Oncology named Dan Calkins as its next chief financial officer. The Boston-based biopharmaceutical company said on Thursday that...

StockNews.com cut shares of Verastem (NASDAQ:VSTM – Free Report) from a hold rating to a sell rating in a research report report published on Wednesday. Several other equities research analysts have also issued reports on VSTM. B. Riley assumed coverage on shares of Verastem in a research report on Wednesday, September 27th. They set a […]

StockNews.com upgraded shares of Verastem (NASDAQ:VSTM – Free Report) from a sell rating to a hold rating in a report issued on Tuesday. A number of other equities analysts have also recently weighed in on the company. Cantor Fitzgerald increased their price target on Verastem from $3.00 to $34.00 in a report on Monday, June […]

StockNews.com cut shares of Verastem (NASDAQ:VSTM – Free Report) from a hold rating to a sell rating in a research report report published on Wednesday morning. VSTM has been the subject of a number of other reports. Cantor Fitzgerald raised their price objective on shares of Verastem from $3.00 to $34.00 in a research report […]

Verastem, Inc. (NASDAQ:VSTM – Get Free Report) was the target of a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 398,200 shares, a growth of 64.8% from the July 15th total of 241,600 shares. Based on an average trading volume of 387,800 shares, the […]

Verastem, Inc. (NASDAQ:VSTM – Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $8.16 and traded as high as $11.18. Verastem shares last traded at $10.22, with a volume of 294,116 shares changing hands. Analysts Set New Price Targets A number of […]

Shares of Verastem, Inc. (NASDAQ:VSTM – Get Free Report) have received an average recommendation of “Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have updated their coverage on the stock in the […]

Verastem, Inc. (NASDAQ:VSTM – Get Free Report) has earned a consensus rating of “Buy” from the six brokerages that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have issued ratings on the stock in the last […]

Verastem, Inc. (NASDAQ:VSTM – Get Free Report) was the target of a large decrease in short interest in July. As of July 15th, there was short interest totalling 241,600 shares, a decrease of 19.5% from the June 30th total of 300,000 shares. Currently, 1.0% of the company’s shares are sold short. Based on an average […]

Mizuho upgraded shares of Verastem (NASDAQ:VSTM – Get Rating) from a neutral rating to a buy rating in a research report released on Thursday, The Fly reports. The firm currently has $36.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $24.00. Several other research firms have also recently weighed […]